Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
October 06, 2014
Cancer Cell

The authors' findings uncover an unexpected neomorphic role for PIK3R1R348 and neighboring truncation mutations in cellular signaling, providing a rationale for therapeutic targeting of these mutant tumors.

CTD²
October 01, 2014
Cancer Discovery

Researchers identify potent siRNAs against RAS to explore potential combination RNAi therapies for KRAS-mutant cancer.

CTD²
September 30, 2014
Scientific Data

When combined with genomic characterization of these cell lines, the dataset presented here facilitates the linkage of genetic dependencies with specific cellular contexts.

CTD²
September 25, 2014
Cell Reports

Using an inducible and reversible transgenic RNAi mouse model, researchers show that strong suppression of the BET protein Brd4 in adult animals has dramatic effects in multiple tissues.

TARGET
September 11, 2014
The New England Journal of Medicine

Genomic profiling and analysis of patients with precursor B-cell ALL and those with Ph-like ALL showed that the genomic alterations that characterized Ph-like ALL might be amenable to inhibition with tyrosine kinase inhibitors. 

CTD²
September 08, 2014
Cancer Cell

Researchers find that inhibition of Aurora kinase A leads to degradation of MYCN protein in MYCN-driven cancers

CTD²
September 01, 2014
Bioinformatics

In this study, researchers address the problem of drug susceptibility prediction against a panel of drugs in a multitask learning framework by formulating a novel Bayesian algorithm that combines kernel-based non-linear dimensionality reduction and binary classification (or regression).

CTD²
August 27, 2014
Genome Biology

Researchers document the metastatic differentiation and genetic heterogeneity of diffuse gastric cancer and reveal the potential metastatic role of TGFBR2 loss-of-function.

CTD²
August 21, 2014
Cell Reports

Researchers find that autocrine IL6 secretion may contribute to MAPK inhibitor resistance in BRAF-mutant cells.

Pages

CSVXML